{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:11:57Z","timestamp":1776125517041,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["3667\/21"],"award-info":[{"award-number":["3667\/21"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jpet.2026.103804","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:04:45Z","timestamp":1768320285000},"page":"103804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural modifications of the tumor necrosis factor-\u03b1 inhibitor Enbrel affect its therapeutic efficacy in a mouse model of rheumatoid arthritis"],"prefix":"10.1016","volume":"393","author":[{"given":"Rachel","family":"Birnboim-Perach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Aharon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Grotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Palgi-Shloosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Diesendruck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitzan","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limor","family":"Nahary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-7177","authenticated-orcid":false,"given":"Itai","family":"Benhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s42358-023-00318-y","article-title":"Extra-articular manifestations of rheumatoid arthritis remain a major challenge: data from a large, multi-centric cohort","volume":"63","author":"Bonfiglioli","year":"2023","journal-title":"Adv Rheumatol"},{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nri.2016.124","article-title":"The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting","volume":"17","author":"Malmstr\u00f6m","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jpet.2026.103804_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102392","article-title":"An overview of autoantibodies in rheumatoid arthritis","volume":"110","author":"van Delft","year":"2020","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.jpet.2026.103804_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.26502\/aimr.0203","article-title":"Factors underlying failure of methotrexate treatment in rheumatoid arthritis: implications in personalized care","volume":"8","author":"Srivastava","year":"2025","journal-title":"Arch Intern Med Res"},{"issue":"4","key":"10.1016\/j.jpet.2026.103804_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2025.102106","article-title":"Contemporary approaches to the management of rheumatoid arthritis: precision and progress","volume":"39","author":"Gudu","year":"2025","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.jpet.2026.103804_bib6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jpet.2026.103804_bib7","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.4049\/jimmunol.152.8.4149","article-title":"Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis","volume":"152","author":"Koch","year":"1994","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2026.103804_bib8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00002281-200207000-00013","article-title":"Pathogenesis of bone erosions in rheumatoid arthritis","volume":"14","author":"Goldring","year":"2002","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib9","first-page":"77","article-title":"In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density","volume":"33","author":"Rossini","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 8","key":"10.1016\/j.jpet.2026.103804_bib10","first-page":"S173","article-title":"TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy","volume":"11","author":"Maini","year":"1993","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.jpet.2026.103804_bib11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.jpet.2026.103804_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.semarthrit.2018.07.011","article-title":"Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence","volume":"48","author":"Mouyis","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jpet.2026.103804_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.gastrohep.2016.01.011","article-title":"Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy","volume":"40","author":"Iriarte","year":"2017","journal-title":"Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jpet.2026.103804_bib14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jpet.2026.103804_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1517\/14712598.2014.896334","article-title":"Etanercept \u2013 TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?","volume":"14","author":"Marotte","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.jpet.2026.103804_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3858\/emm.2011.43.10.063","article-title":"One target, different effects: a comparison of distinct therapeutic antibodies against the same targets","volume":"43","author":"Shim","year":"2011","journal-title":"Exp Mol Med"},{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.jidsymp.5650035","article-title":"Construction and purification of the murine p75-murine IgG1 fusion protein","volume":"12","author":"Kim","year":"2007","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.jidsymp.5650030","article-title":"Pharmacodynamic effects of the murine p75-Fc fusion protein in mice","volume":"12","author":"Hu","year":"2007","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"5","key":"10.1016\/j.jpet.2026.103804_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/ar4319","article-title":"Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse","volume":"15","author":"Doll","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jpet.2026.103804_bib21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/978-1-4939-8958-4_23","article-title":"Production of stabilized antibody fragments in the E. coli bacterial cytoplasm and in transiently transfected mammalian cells","volume":"1904","author":"Birnboim-Perach","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"6","key":"10.1016\/j.jpet.2026.103804_bib22","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s10439-024-03478-0","article-title":"Microfluidic diffusional sizing (MDS) measurements of secretory neutralizing antibody affinity against SARS-CoV-2","volume":"52","author":"O\u2019Mahoney","year":"2024","journal-title":"Ann Biomed Eng"},{"issue":"3","key":"10.1016\/j.jpet.2026.103804_bib23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3892\/etm.2021.10371","article-title":"Applicability and implementation of the collagen-induced arthritis mouse model, including protocols (Review)","volume":"22","author":"Luan","year":"2021","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/019262339902700125","article-title":"Animal models of arthritis: relevance to human disease","volume":"27","author":"Bendele","year":"1999","journal-title":"Toxicol Pathol"},{"issue":"5","key":"10.1016\/j.jpet.2026.103804_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/ard.2003.013599","article-title":"Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA\/1 mice: a model of psoriatic arthritis","volume":"63","author":"Lories","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jpet.2026.103804_bib26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/opo.12131","article-title":"When to use the Bonferroni correction","volume":"34","author":"Armstrong","year":"2014","journal-title":"Ophthalmic Physiol Opt"},{"issue":"4","key":"10.1016\/j.jpet.2026.103804_bib27","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1213\/ANE.0000000000004373","article-title":"Two-sample unpaired t tests in medical research","volume":"129","author":"Schober","year":"2019","journal-title":"Anesth Analg"},{"issue":"11","key":"10.1016\/j.jpet.2026.103804_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.111","article-title":"TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members","volume":"2","author":"Vanlangenakker","year":"2011","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tibtech.2014.11.001","article-title":"Fc fusion as a platform technology: potential for modulating immunogenicity","volume":"33","author":"Levin","year":"2015","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.jpet.2026.103804_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/19420862.2015.1113360","article-title":"Pharmacokinetic properties of IgG and various Fc fusion proteins in mice","volume":"8","author":"Unverdorben","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.jpet.2026.103804_bib32","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3389\/fimmu.2017.01287","article-title":"Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors","volume":"8","author":"Xenaki","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpet.2026.103804_bib33","article-title":"B cells in rheumatoid arthritis: pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jpet.2026.103804_bib34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/ard.2009.122655","article-title":"IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy","volume":"69","author":"Verri","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpet.2026.103804_bib35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fimmu.2011.00052","article-title":"Macrophages in synovial inflammation","volume":"2","author":"Kennedy","year":"2011","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jssc.202000765","article-title":"Therapeutic Fc-fusion proteins: current analytical strategies","volume":"44","author":"Duivelshof","year":"2021","journal-title":"J Sep Sci"},{"key":"10.1016\/j.jpet.2026.103804_bib37","first-page":"30","article-title":"Immunoglobulin fc-fusion proteins part 1: their design and manufacture","volume":"12","author":"Linderholm","year":"2014","journal-title":"Bioprocess Int"},{"issue":"496","key":"10.1016\/j.jpet.2026.103804_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.jpet.2026.103804_bib39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.jpet.2026.103804_bib40","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3389\/fimmu.2017.01860","article-title":"Engineering of Fc fragments with optimized physicochemical properties implying improvement of clinical potentials for Fc-based therapeutics","volume":"8","author":"Yang","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpet.2026.103804_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2021.671728","article-title":"The instability of dimeric Fc-fusions expressed in plants can be solved by monomeric Fc technology","volume":"12","author":"Gattinger","year":"2021","journal-title":"Front Plant Sci"},{"key":"10.1016\/j.jpet.2026.103804_bib42","series-title":"Single Chain Fc Fusion Proteins","author":"Alvarez","year":"2021"},{"issue":"1","key":"10.1016\/j.jpet.2026.103804_bib43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12974-023-02974-9","article-title":"An engineered Fc fusion protein that targets antigen-specific T cells and autoantibodies mitigates autoimmune disease","volume":"20","author":"Janakiraman","year":"2023","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jpet.2026.103804_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1385085","article-title":"C-reactive protein lowers the serum level of IL-17, but not TNF-\u03b1, and decreases the incidence of collagen-induced arthritis in mice","volume":"15","author":"Singh","year":"2024","journal-title":"Front Immunol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:28:11Z","timestamp":1776122891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0022356526000029"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.103804","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural modifications of the tumor necrosis factor-\u03b1 inhibitor Enbrel affect its therapeutic efficacy in a mouse model of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.103804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103804"}}